Genenta signs Definitive Agreements with Sophia High Tech
Genenta enters aerospace as it continues its strategic transformation into a next-generation industrial consolidatorMILAN,Italy, April 23, 2026 (GLOBE NEWSWIRE) --...
Day: April 23, 2026
Antag Therapeutics to present data on AT7687, its first-in-class GIPR antagonist peptide at the American Diabetes Association’s 2026 Scientific Sessions
Copenhagen, Denmark, 23 April 2026 – Antag Therapeutics (“Antag” or “the Company”), advancing personalized and flexible obesity treatment through GIP...
Radiopharm Theranostics Reports Business Update
Completed enrolment in Phase 2b clinical trial of imaging agent RAD 101 in patients with recurrent brain metastases following earlier...
Jade Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO and VANCOUVER, British Columbia, April 23, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq:...
Transcenta Therapeutics Presents New Data for its Novel LIV1-Targeting ADC TST013 Demonstrating Potent Anti-Tumor Activity in PDX Models of Prostate Cancer and ER Positive /HER2 Negative Breast Cancer
PRINCETON, N.J. and SUZHOU, China, April 23, 2026 (GLOBE NEWSWIRE) -- Transcenta Therapeutics (HKEX: 06628), a global clinical stage biopharmaceutical...
Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder
Dosing initiates clinical evaluation of NPX-5, a GMP-compliant, nature-derived psilocybin candidate across an expanded Australian site networkNEW YORK, April 23,...
Verano Expands Retail Presence on Florida’s Emerald Coast with Opening of MÜV Miramar Beach, the Company’s 85th Florida Dispensary and 162nd Location Nationwide
MÜV Miramar Beach, located on a busy stretch of scenic Highway 98 with an average daily traffic count of 48,000...
AAVantgarde to Participate in ARVO 2026, with Presentations at Key Pre-events and New Clinical Data from the LUCE Phase 1/2 Study
MILAN, April 23, 2026 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company pioneering next-generation gene therapies for inherited...
Tonix Pharmaceuticals Presents Updates on Preclinical Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2026
TNX-1700 (TFF2-albumin fusion protein) reversed aging-associated gastric inflammation and significantly attenuated tumor progression in aged gastric microenvironment in preclinical models...
Validic Launches Free Developer Tier with API-Driven, Agentic-Ready Self-Signup
The connected health data company opens its health data platform to every developer and builder, with full support for agentic...
BrewDog USA Doubles Down on Headliners and Ignites Next Wave of Innovation for Spring and Summer
BrewDog Elvis Juice BrewDog Elvis Juice BrewDog 95 BrewDog 95 BrewDog Juice Club BrewDog Juice Club BrewDog Juice Club BrewDog...
Aveanna Announces First Quarter 2026 Earnings Release Date and Conference Call
ATLANTA, April 23, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that the company will...
Greenwich LifeSciences Announces Acceptance of Abstract at ASCO 2026
STAFFORD, Texas, April 23, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused...
Novo Nordisk’s oral semaglutide demonstrates potential to be the first oral GLP-1 RA therapy for children and adolescents with type 2 diabetes
PIONEER TEENS is the first clinical trial of an oral GLP-1 RA therapy in children and adolescents aged 10–17 years...
Orion Group Interim report January–March 2026
ORION CORPORATION INTERIM REPORT 1–3/2026 23 APRIL 2026 at 12:00 EEST Orion Group Interim report January–March 2026 January–March 2026 Highlights...
Restart Life Sciences’ Wholly Owned Subsidiary Holy Crap Foods Reports over 500,000 Units Sold, Highlighting Strong Consumer Adoption
Vancouver, British Columbia--(Newsfile Corp. - April 23, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF)...
Restart Life Sciences’ Wholly Owned Subsidiary Holy Crap Foods Reports over 500,000 Units Sold, Highlighting Strong Consumer Adoption
Vancouver, British Columbia--(Newsfile Corp. - April 23, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF)...
Psyched Wellness Highlights U.S. Federal Policy Momentum Supporting Psychedelic Sector
Toronto, Ontario--(Newsfile Corp. - April 23, 2026) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company"), a...
Psyched Wellness Highlights U.S. Federal Policy Momentum Supporting Psychedelic Sector
Toronto, Ontario--(Newsfile Corp. - April 23, 2026) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company"), a...
Optimi Health Files LIFE Offering Document in Connection with NASDAQ Listing
Vancouver, British Columbia--(Newsfile Corp. - April 23, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (the "Company"...